HR Execs on the Move

Advanced Infusion Solutions Care Group

www.aiscaregroup.com

 
As the leading provider of targeted drug delivery (TDD) and infusion care, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected across our two divisions. ● A center of excellence in high-risk intrathecal compounding, AIS Healthcare Targeted Drug Delivery prepares and ships more than 140,000 patient-specific dispenses annually to all 50 states. We also offer comprehensive care services to support patients and empower providers, including in-home pump care and care coordination services. ● At Advanced Infusion Care, we ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Greg Bradley
Senior Vice President, Head of Marketing and Sales Effectiveness Profile
Chad Jeske
Vice President, Head of Sales Profile

Similar Companies

Pediatric Associates

Pediatric Associates has been caring for infants, children and adolescents since 1955. Pediatric Associates opened its first office in Hollywood, FL. Since then, our physicians have cared for four generations of families with our first patients now bringing their children, grandchildren and great-grandchildren to our practice. From South Florida to Tampa and Jacksonville, across the state of Florida and now across the country, Pediatric Associates has more than 200 locations nationwide.

Santaris Pharma A/S USA

Santaris Pharma A/S USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Higher Dimension Research

Higher Dimension Research is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Embecta

Embecta will be the name of the independent, publicly-traded company that will hold BD`s Diabetes Care business

RedHill Biopharma

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force of approximately 40 sales representatives promoting two speciality gastrointestinal products in select U.S. territories. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise. '